Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON: durvalumab + tremelimumab with platinum-doublet chemotherapy for early relapse after chemoradiotherapy and durvalumab in unresectable locally advanced NSCLC
jRCTs061240019Phase 2Active, not recruiting
- Sponsor
- North East Japan Study Group
- Start
- Jun 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, tremelimumab, cisplatin, carboplatin, pemetrexed and 1 more in non-small cell lung cancer (NSCLC) (3 arms), sponsored by North East Japan Study Group. Primary endpoint: Objective response rate. Started Jun 2024; status: active, not recruiting.
02
Drugs
durvalumabtremelimumabcisplatincarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061240019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240019.